{"id":"mistletoe-extract-iscador-qu","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Flu-like symptoms"}]},"_chembl":{"chemblId":"CHEMBL2108766","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Iscador Qu contains bioactive compounds including lectins and viscotoxins that enhance innate and adaptive immune responses against malignant cells. The extract promotes cytokine production, increases natural killer cell activity, and may induce apoptosis in cancer cells. It is used as an adjunctive immunotherapy in cancer treatment to improve survival and quality of life.","oneSentence":"Mistletoe extract (Iscador Qu) stimulates the immune system to recognize and attack cancer cells through activation of natural killer cells and other immune effectors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:31.738Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive treatment in various solid tumors (breast, lung, colorectal, ovarian cancer)"},{"name":"Improvement of quality of life and survival in cancer patients"}]},"trialDetails":[{"nctId":"NCT05726383","phase":"PHASE2","title":"Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2024-05-14","conditions":"Osteogenic Sarcoma Recurrent","enrollment":32},{"nctId":"NCT06408688","phase":"PHASE4","title":"Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2024-06-24","conditions":"Advanced Solid Tumor","enrollment":100},{"nctId":"NCT02948309","phase":"PHASE3","title":"Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2016-06","conditions":"Pancreatic Cancer","enrollment":290},{"nctId":"NCT04376931","phase":"PHASE1, PHASE2","title":"A Prospective Dose Finding Study of Iscador Infusion","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2020-12-01","conditions":"Advanced Cancer","enrollment":24},{"nctId":"NCT00176046","phase":"PHASE4","title":"Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"1999-05","conditions":"Metastatic Breast Cancer","enrollment":114},{"nctId":"NCT01448655","phase":"","title":"Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)","status":"UNKNOWN","sponsor":"IFAG AG","startDate":"2010-09","conditions":"Colorectal Cancer","enrollment":300},{"nctId":"NCT01448668","phase":"","title":"Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)","status":"UNKNOWN","sponsor":"IFAG AG","startDate":"2010-09","conditions":"Pancreas Cancer","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fermented aqueous extract of Viscum album ssp album (L.)"],"phase":"phase_3","status":"active","brandName":"Mistletoe extract (Iscador Qu)","genericName":"Mistletoe extract (Iscador Qu)","companyName":"Karolinska University Hospital","companyId":"karolinska-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mistletoe extract (Iscador Qu) stimulates the immune system to recognize and attack cancer cells through activation of natural killer cells and other immune effectors. Used for Adjunctive treatment in various solid tumors (breast, lung, colorectal, ovarian cancer), Improvement of quality of life and survival in cancer patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}